All In Biotech

Drug Trial Radar · NCT05827081

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,466

Actual

Start

Feb 28, 2024

Primary completion

Sep 7, 2029

Study completion Sep 20, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Conditions

  • Early Breast Cancer

Interventions

  • RibociclibDrug

    Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest

  • LetrozoleDrug

    Letrozole 2.5 mg orally once daily continuously

  • AnsastrozoleDrug

    Anastrozole 1 mg orally once daily continuously.

  • GoserelinDrug

    Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used

  • LeuprolideDrug

    Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used

  • ExemestaneDrug

    Exemestane 25 mg once daily continuously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Breast Cancer Free Survival (iBCFS) rate at 3 yearsTime frame: At 3 years

Locations

214 sites in 16 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Western Reg MC-COH Phoenix

    Goodyear, Arizona

  • CARTI Cancer Center

    Little Rock, Arkansas

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Onco Inst of Hope and Innovation

    Cerritos, California

  • City of Hope National Medical

    Duarte, California

  • Providence Medical Foundation

    Fullerton, California

  • Los Angeles Cancer Network Good Samaritan

    Los Angeles, California

  • El Camino Hospital

    Mountain View, California

  • Palo Alto Medical Foundation

    Mountain View, California

  • UC Irvine Medical Center

    Orange, California

  • Sutter Inst Medical Research

    Sacramento, California

  • School Of Medicine

    Sacramento, California

  • Sharp Rees Stealy Medical Group Inc

    San Diego, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Georgetown University Lombardi Cancer Center

    Washington D.C., District of Columbia

  • Medstar Washington Hospital Center

    Washington D.C., District of Columbia

  • AdventHealth Altamonte Springs

    Altamonte Springs, Florida

  • Holy Cross Health

    Fort Lauderdale, Florida

  • Hialeah Hospital

    Hialeah, Florida

  • Memorial Cancer Institute

    Hollywood, Florida

  • Jupiter Medical Center

    Jupiter, Florida

  • Ocala Research Institute Inc

    Ocala, Florida

  • Summit Cancer Care PC

    Savannah, Georgia

  • Affiliated Oncologists IL

    Chicago, Illinois

  • Hope And Healing Care

    Hinsdale, Illinois

  • Midwestern Reg MC COH Chicago

    Zion, Illinois

  • Investigative Clinical R of Indiana

    Indianapolis, Indiana

  • University of Iowa Health Care

    Waukee, Iowa

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • Willis-Knighton Cancer Center

    Shreveport, Louisiana

  • Mercy Medical Center

    Baltimore, Maryland

  • Maryland Oncology Hematology P A

    Silver Spring, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Minnesota Oncology Hematology P A

    Minneapolis, Minnesota

  • Allina Hlth Cancer Inst Minneapolis

    Minneapolis, Minnesota

  • Jackson Oncology Associates

    Jackson, Mississippi

Showing 40 of 214 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.